Back to top

biotechs: Archive

Debanjana Dey

BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?

bioAffinity's CyPath Lung sales momentum is gaining traction, but wider losses, funding needs and regulatory risks keep pressure on the stock.

BIAFNegative Net Change ADMANegative Net Change ALXONegative Net Change

Ethan Feller

Stocks Look Shaky, But This Sector is Booming (Biotech)

Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.

LLYNegative Net Change ILMNNegative Net Change EXELNegative Net Change XLVPositive Net Change PTCTNegative Net Change XBINegative Net Change FTREPositive Net Change

Zacks Equity Research

PRTA Stock Rises Nearly 11% in Six Months: What's Driving It?

Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.

PRTANegative Net Change RHHBYNegative Net Change BMYPositive Net Change NVONegative Net Change

Zacks Equity Research

TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know

Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerability, target engagement and support plans for mid-stage development.

TVRDPositive Net Change NVAXNegative Net Change AMRNNegative Net Change LQDANegative Net Change

Zacks Equity Research

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?

Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.

NTLANegative Net Change BEAMNegative Net Change CRSPNegative Net Change

Sundeep Ganoria

Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation?

Viking Therapeutics' expanding obesity pipeline and upcoming VK2735 data reignite buyout speculation as investors weigh its growing strategic appeal.

VKTXNegative Net Change NVONegative Net Change LLYNegative Net Change

Zacks Equity Research

AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study

AZN shares tumble after Wainua missed the primary endpoint in a late-stage ATTR-CM study, raising questions about its expansion into a larger market.

AZNNegative Net Change ALNYNegative Net Change IONSNegative Net Change BBIONegative Net Change

Zacks Equity Research

DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?

Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.

DNLIPositive Net Change SNYPositive Net Change BIIBPositive Net Change TAKNegative Net Change

Ekta Bagri

Is ADMA Stock's 13.5% Monthly Gain a Sign of Recovery?

ADMA shares rebound 13.5% in a month after a steep decline, even as lowered 2026 guidance and IG market competition continue to weigh on sentiment.

ADMANegative Net Change GRFSNegative Net Change TAKNegative Net Change

Sundeep Ganoria

BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth

BBIO builds on Attruby's launch as rising rare disease diagnoses and late-stage pipeline candidates set up multiple potential U.S. launches.

BBIONegative Net Change PFEPositive Net Change BMRNPositive Net Change ASNDNegative Net Change